Official Title
Inflammatory Cytokine Profile in Maintenance Hemodialysis Patients Affected by COVID-19: Effects of 2 Different Dialysis Strategies
Brief Summary

In the course of Coronavirus Disease-19 (COVID-19) uncontrolled inflammation has been related to disease severity and unfavorable outcomes. Here, the investigators study the longitudinal changes of pro- and anti-inflammatory markers in a population of patients undergoing maintenance hemodialysis (HD) affected by COVID-19, evaluating the potential modulating effects of two different dialysis approaches

Detailed Description

For this prospective randomized study, the investigators recruit maintenance hemodialysis
patients with confirmed COVID-19 infection. After diagnosis, the patients are randomized to
two different dialysis modalities, expanded HD (HDx), performed by use of a medium cut-off
membrane, and standard treatment based on the use of a protein-leaking dialyzer (PLD).

The investigators collect clinical and laboratory data, including circulating pre and
post-dialysis levels of interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-10 (IL-10),
soluble TLR4 (sTLR4), and interferon-gamma (IFN-g). Samples are collected at diagnosis (T0),
and one and two weeks after the diagnosis (T7 and T14, respectively). Moreover, lymphocyte
and immune cell profiles are evaluated.

Completed
COVID19
Hemodialysis Complication
Inflammatory Response

Procedure: Expanded Hemodialysis for Covid19 maintenance hemodialysis patients

After Covid19 diagnosis participants are randomized to receive Expanded Hemodialysis for two weeks

Procedure: Hemodialysis by protein-leaking dialyzer for Covid19 maintenance hemodialysis patients

After Covid19 diagnosis participants are randomized to receive hemodialysis by protein-leaking dialyzer for two weeks

Eligibility Criteria

Inclusion Criteria:

- Patients undergoing maintenance hemodialysis

- Confirmed severe acute respiratory syndrome-coronavirus2 infection

Exclusion Criteria:

- Acute kidney injury

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A
Countries
Italy
Locations

Ospedale IRCCS San Martino
Genova, Italy

Policlinico IRCCS Ospedale San Matteo
Pavia, Italy

Francesca Viazzi, MD, Study Director
Unit of Nephrology, Dept Internal Medicine, Univerity of Genova and San Martino Hospital

IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
NCT Number
Keywords
Hemodialysis
COVID19
inflammation
MeSH Terms
COVID-19